Nancy A. Grygiel, an insider at Amgen Inc (AMGN), acquired 8,725 shares of the biotechnology company on November 19, 2025, at a price of $177.46 per share, amounting to a total investment of $1.55 million. Following this transaction, Grygiel holds a total of 8,725 shares in the company.
Amgen, headquartered in Thousand Oaks, California, focuses on the discovery, development, manufacture, and marketing of human therapeutics. The company operates in the human therapeutics segment and employs approximately 28,000 full-time staff. Its portfolio includes well-known products such as EPOGEN, Neulasta, and Repatha, addressing significant medical needs across various therapeutic areas.
This insider purchase may be interpreted as a sign of confidence in Amgen's prospects, as executives often have access to non-public information regarding company performance. However, it is essential for investors to consider insider transactions within the broader context of market conditions and other financial indicators.
Amgen currently boasts a market capitalization of $184.4 billion, with a P/E ratio of 26.32 and an EPS of 12.94. The company has a dividend yield of 278.0%. Looking ahead, Amgen's upcoming earnings report is scheduled for August 3, 2026, with an estimated EPS of $5.80 and projected revenue of $9.5 billion. Investors should analyze insider activity across multiple periods and individuals to better understand market signals.